Tudor Investment Corp ET AL Lowers Holdings in STERIS plc $STE

Tudor Investment Corp ET AL trimmed its holdings in STERIS plc (NYSE:STE) by 91.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,807 shares of the medical equipment provider’s stock after selling 18,628 shares during the quarter. Tudor Investment Corp ET AL’s holdings in STERIS were worth $447,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of STERIS by 0.4% during the third quarter. Vanguard Group Inc. now owns 12,213,521 shares of the medical equipment provider’s stock worth $3,022,114,000 after acquiring an additional 50,393 shares during the last quarter. State Street Corp raised its position in STERIS by 4.0% during the third quarter. State Street Corp now owns 4,354,839 shares of the medical equipment provider’s stock valued at $1,077,564,000 after purchasing an additional 166,736 shares during the period. Orbis Allan Gray Ltd lifted its stake in shares of STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of STERIS by 16.4% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,567,238 shares of the medical equipment provider’s stock worth $387,797,000 after purchasing an additional 221,199 shares during the period. Finally, Invesco Ltd. increased its position in shares of STERIS by 4.9% during the 3rd quarter. Invesco Ltd. now owns 1,280,142 shares of the medical equipment provider’s stock valued at $316,758,000 after purchasing an additional 59,443 shares during the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Price Performance

NYSE STE opened at $220.01 on Thursday. The company has a market cap of $21.58 billion, a price-to-earnings ratio of 30.68 and a beta of 1.07. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.48 and a quick ratio of 1.75. The stock’s fifty day moving average price is $240.19 and its 200 day moving average price is $248.16. STERIS plc has a 1 year low of $204.90 and a 1 year high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $2.53 EPS for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a return on equity of 14.34% and a net margin of 12.15%.The company’s revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.32 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. As a group, equities research analysts forecast that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th were issued a $0.63 dividend. The ex-dividend date was Tuesday, February 17th. This represents a $2.52 dividend on an annualized basis and a yield of 1.1%. STERIS’s dividend payout ratio is presently 35.15%.

Wall Street Analyst Weigh In

Several research firms have issued reports on STE. Wall Street Zen cut shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 28th. Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Friday, January 9th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

Insiders Place Their Bets

In other STERIS news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at $167,233.05. This trade represents a 81.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.07% of the stock is owned by company insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.